Table 5.

Univariate analysis of factors associated with 30-day mortality of patients with candidaemia

Characteristics	Survivors n = 134 (74.4%)	Deaths n = 46 (25.6%)	P Value
Age	61.5 ± 15.3	63 ± 17.8	0.570
Male sex	90 (67.2%)	32 (69.6%)	0.764
Underlying diseases
Haematological malignancy	3 (2.2%)	4 (8.7%)	0.130
Solid tumours	67 (50%)	13 (28.3%)	0.010
Diabetes mellitus	30 (22.4%)	11 (23.9%)	0.831
Predisposing factors
Dialysis	7 (5.2%)	1 (2.2%)	0.652
Current and former smokers	42 (31.3%)	12 (26.1%)	0.502
ICU stay	25 (18.7%)	31 (67.4%)	<0.001
Surgical patients	107 (79.9%)	31 (67.4%)	0.085
Recent abdominal surgery	88 (65.7%)	20 (43.5%)	0.008
Recent cancer surgery	63 (47%)	8 (17.4%)	<0.001
Prior antibiotics exposure	119 (88.8%)	44 (95.7%)	0.281
Prior antifungal exposure	20 (14.9%)	6 (13%)	0.754
TPN	112 (83.6%)	40 (87%)	0.586
Presence of CVC	42 (31.3%)	26 (56.5%)	0.002
Mechanical ventilation	6 (4.5%)	6 (13%)	0.096
Presence of urethral catheter	88 (65.7%)	27 (58.7%)	0.395
Presence of gastric tube	95 (70.9%)	27 (58.7%)	0.127
Laboratory findings
Renal failure	19 (14.2%)	19 (41.3%)	<0.001
Anaemia	109 (81.3%)	39 (84.8%)	0.599
Hypoalbuminaemia	42 (31.3%)	28 (60.9%)	<0.001
Hyponatraemia	60 (44.8%)	8 (17.4%)	0.001
Leukopaenia	16 (11.9%)	9 (19.6%)	0.197
Thrombocytopaenia	10 (7.5%)	18 (39.1%)	<0.001
C. albicans	41 (30.6%)	23 (50%)	0.018
Fluconazole susceptibility	99 (73.9%)	30 (65.2%)	0.261
Empirical antifungal therapy	89 (66.4%)	29 (63%)	0.678
No antifungal therapy	17 (12.7%)	8 (17.4%)	0.426
Outcome
LOS (days)	30 (21–48)	27.5 (16–41.3)	0.191

ICU, intensive care unit; TPN, total parenteral nutrition; CVC, central venous catheter; LOS, length of hospital stay.